Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01181193 : Vitamin D for Treatment of Glioblastoma Multiforme
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

1. Age > 18 years

2. Newly-diagnosed, histologically confirmed GBM

3. Surgical procedures: craniotomy with gross tumour resection or maximal debulking

4. Brain lesion suitable suitable for radical 3-DCRT/IMRT according to tumour location
and size.

5. Karnofsky performance status (KPS) > 70 (ECOG/WHO 0-1)

6. No previous RT to brain

7. No serious comorbid condition

8. No treatment with biological response modifiers or cytotoxic agents within four weeks
prior to study entry

9. No participation in clinical trial using any investigational drug or device within
four weeks prior to study entry

10. No serious complication of malignant condition

11. No previous or concurrent malignancy at other sites, except cone biopsied in situ
carcinoma of the uterine cervix and adequately treated basal cell or squamous cell
carcinoma of the skin

12. Adequate organ function as evidenced by the following peripheral blood counts or
serum chemistries at study entry:

- Hemoglobin > 9.0 Gm/dL

- WBC count > 4.0x109/L

- Neutrophile count > 1.5 cells x 109/L,

- Platelet count > 100 x 109/L,

- Creatinine < 1.5 mg/dL

- Total bilirubin < ULN (upper limit of normal)

- AST/SGOT < ULN

- Calcium < ULN

13. Ability to sign informed consent

14. Ability to attend follow-up visits

Exclusion Criteria:

1. Surgical procedures: only stereotactic biopsy

2. Brain lesion not suitable for 3-DCRT/IMRT

3. KPS < 70 (ECOG/WHO <2)

4. Previous RT to brain

5. Treatment with biological response modifiers or cytotoxic agents within four weeks
prior to study entry

6. Participation in clinical trial using any investigational drug or device within 7
weeks prior to study entry

7. Major surgical procedure within two weeks prior to study entry

8. Serious comorbid condition, inclusive but not limited to myocardial infarction within
previous six months, uncontrolled cardiac arrhythmias, uncontrolled angina pectoris,
active infection including acute hepatitis

9. Serious complication of malignant condition

10. Previous or concurrent malignancy

11. Known hypersensitivity to vitamin D

12. Inadequate organ function as evidenced by the following peripheral blood counts or
serum chemistries at study entry:

- Hemoglobin < 9.0 Gm/dL

- WBC count < 4.0x109/L

- Neutrophile count < 1.5 cells x 109/L,

- Platelet count < 100 x 109/L,

- Creatinine > 1.5 mg/dL

- Total bilirubin > ULN (upper limit of normal)

- AST/SGOT > ULN

- Calcium > ULN

13. Inability to sign informed consent

14. Psychological, familial, sociological or geographical conditions which do not permit
regular medical follow-up and compliance with the protocol.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01181193      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740